ASN Kidney Week - American Society of Nephrology Kidney Week

Results demonstrating safety and efficacy in those with anemia in non-dialysis dependent chronic kidney disease and anemia in dialysis-dependent chronic kidney disease were presented at the 2024 American Society of Nephrology Kidney Week.

A low carbohydrate diet plus a sodium glucose contransporter-2 (SGLT2) inhibitor was found to be safe and effective for weight loss and glycemic control in patients with diabetes and chronic kidney disease.

Although SGLT2 inhibitors are not a cure of diabetic kidney disease, this treatment can help reduce the risk and manage the disease either alone or with complementary therapies.

Deep-rooted discrimination and stigma can contribute to stressors that worsen disease progression and access to care, according to experts.

Other than dialysis, Shah notes that patients with kidney disease who are pregnant can receive either nifedipine or labetalol to control blood pressure.

Nickolas also describes how the use of novel imaging technologies, microRNA, and transcriptomics help experts better understand underlying pathogenesis of ROD.

Understanding the mechanisms leading to weight loss could help identify potential benefits for cardiorenal health in patients with chronic kidney disease.

Sodium-glucose cotransporter-2 inhibitors and sodium zirconium cyclosilicate may be paired with these kidney disease medications to reduce high serum potassium.

Exercise has the potential to improve physical performance and fitness at the very least, but a multidisciplinary intervention may work better for patients with chronic kidney disease.

Awdishu describes the implementation of new equations to accurately drug dose in patients as well as provide updated guidance on the dosing of older medications.

Leung discusses that various cancer types and drugs can cause thrombotic microangiopathy and impact kidney health and the renal complications connected to hematologic malignancies.

Nephrotoxic care can be improved with better risk score assessment and provider education.

Improvements in AI could change the way pharmacists and providers interact with, and care for, patients.

Coca notes the importance of precision medicine in CKD risk assessment and describes the potential impact multiple therapies can have on future CKD prediction and treatment in the future.

The principal investigator of the Centre for Cardiovascular Science at the University of Edinburgh notes that enhancing endogenous repair can lead to a breakthrough in AKI treatment.

The increased costs for patients with recurrent hyperkalemia were driven by the increased inpatient medical cost of additional time spent in the hospital following recurrence.

An analysis of the REVOLUTIONIZE II study data showed that there is an unmet need for long-term outpatient treatment of hyperkalemia in patients with CKD.

Outside of dialysis and transplantations, implantable artificial kidneys present an additional option for treating kidney disease, according to an expert.

Pharmacy Times will be at the American Society for Nephrology’s (ASN) 2023 Kidney Week Annual Meeting in Philadelphia, Pennsylvania, from November 2 to 5.

Controlling blood pressure may be the most important type of treatment for vasculitis and lupus patients, said a professor of renal medicine at ASN Kidney Week in Orlando, Florida.

Daprodustat is suggested to improve anemia and quality-of-life in patients with chronic kidney disease.

Active patient care with chronic kidney disease may provide enormous benefits for patients, the economy, and society.

Next-generation research shows that targeting specific Kir channels, which regulate salt reabsorption in the kidneys, could improve diuretic function in kidney patients.

Healthcare practitioner finds that institutions need to acknowledge advantaged and disadvantaged groups of patients as motivation to overcome systemic barriers.

Pharmacists should get out from behind the glass from time to time and work with chronic kidney disease patients to better understand their medications and lifestyle decisions, said an analyst who spoke at ASN Kidney Week in Orlando, Florida.

Researchers outline new findings about the connection between hyperkalemia and renin-angiotensin-aldosterone system inhibitors during a session at ASN Kidney Week.

Applying the principles of precision medicine to peritoneal dialysis could improve the flexibility and personalization of care for dialysis patients.

Education, awareness, and more training may help more pharmacists and kidney patients consider home dialysis as an effective treatment option, said an expert on November 4 at ASN Kidney Week in Orlando, Florida.

Researcher suggests that medications for high blood pressure may be useful in treating patients with slow-onset immunoglobulin A nephropathy, a topic he will present on this weekend at ASN Kidney Week in Orlando, Florida.

Daniel Weiner, MD, MS, associate professor at Tufts University, discusses effective treatment approaches for diabetic kidney disease at ASN Kidney Week.